enGene Holdings Inc. (NASDAQ:ENGN) Receives Average Recommendation of "Buy" from Analysts

Shares of enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) have earned an average rating of "Buy" from the ten brokerages that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, eight have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $25.22.

A number of research firms have recently weighed in on ENGN. UBS Group downgraded enGene from a "buy" rating to a "neutral" rating and cut their price target for the stock from $34.00 to $7.00 in a research note on Friday, February 14th. JMP Securities restated a "market outperform" rating and set a $18.00 price target on shares of enGene in a research note on Monday, December 23rd. Piper Sandler initiated coverage on shares of enGene in a research note on Tuesday, February 18th. They issued an "overweight" rating and a $26.00 price objective for the company. Morgan Stanley lowered their target price on shares of enGene from $37.00 to $34.00 and set an "overweight" rating on the stock in a research report on Tuesday, March 11th. Finally, Raymond James assumed coverage on enGene in a research report on Wednesday, November 27th. They issued an "outperform" rating and a $23.00 price target for the company.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ENGN. Franklin Resources Inc. grew its position in enGene by 48.7% during the third quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company's stock worth $7,854,000 after buying an additional 389,918 shares in the last quarter. Point72 Asset Management L.P. raised its stake in shares of enGene by 1,410.3% in the third quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company's stock valued at $4,376,000 after purchasing an additional 619,100 shares in the last quarter. Vontobel Holding Ltd. bought a new position in enGene in the fourth quarter worth $69,000. VR Adviser LLC boosted its stake in enGene by 41.5% during the fourth quarter. VR Adviser LLC now owns 5,046,414 shares of the company's stock worth $33,559,000 after buying an additional 1,480,573 shares in the last quarter. Finally, Cubist Systematic Strategies LLC increased its holdings in enGene by 15.7% in the 4th quarter. Cubist Systematic Strategies LLC now owns 15,342 shares of the company's stock valued at $102,000 after buying an additional 2,080 shares during the period. Institutional investors own 64.16% of the company's stock.

Remove Ads

enGene Trading Up 1.1 %

Shares of enGene stock traded up $0.06 on Friday, reaching $5.21. 20,298 shares of the company were exchanged, compared to its average volume of 131,043. The company has a current ratio of 16.87, a quick ratio of 16.87 and a debt-to-equity ratio of 0.08. enGene has a fifty-two week low of $4.42 and a fifty-two week high of $18.40. The firm has a market capitalization of $265.54 million, a price-to-earnings ratio of -8.97 and a beta of -0.61. The stock has a fifty day moving average price of $6.41 and a 200-day moving average price of $7.10.

enGene (NASDAQ:ENGN - Get Free Report) last announced its quarterly earnings data on Thursday, December 19th. The company reported ($0.34) EPS for the quarter, beating analysts' consensus estimates of ($0.40) by $0.06. On average, analysts expect that enGene will post -1.56 EPS for the current year.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.